{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:12:37Z","timestamp":1789171957569,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>To evaluate the clinical outcomes of eplerenone in the management of acute central serous chorioretinopathy (CSCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>This case\u2013control study involved 52 eyes of 52 cases of acute CSCR divided between treatment (26) and control (26) groups. Cases in the treatment group were managed by tablet eplerenone 50 mg\/d. During the scheduled visits, serum electrolytes and an ophthalmic evaluation, including optical coherence tomography, were conducted. The control group was subject to observation and a similar follow-up. The Statistical Programme for Social Sciences, version 23 was used for statistical tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      The mean age in the treatment and control group was 39.15 \u00b1 12.1 years and 36.1 \u00b1 8.09 years, respectively. In the treatment group, 46.15% of right eyes and 53.8% of left eyes, and in the control group, 61.5% of right eyes and 38.5% of left eyes were evaluated. Visual acuity improved to 6\/6 in 96.2% of treated cases and 19.2% of controls in the 2\n                      <jats:sup>nd<\/jats:sup>\n                      month of follow-up. Subretinal fluid resolved completely in 61.52% of treated cases and 38.46% of controls at 12-week follow-up. No adverse events were reported, and by the 12\n                      <jats:sup>th<\/jats:sup>\n                      week of follow-up, the mean serum K+ was 4.80 \u00b1 0.157 mEq\/L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Acute CSCR cases managed with oral eplerenone can attain faster resolution with significant functional improvement. Eplerenone may serve as a first-line therapeutic option for acute CSCR with a better safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ojo.ojo_118_23","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:01:59Z","timestamp":1740459719000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcome of eplerenone in the management of acute central serous chorioretinopathy"],"prefix":"10.4103","volume":"18","author":[{"given":"Pramod Kumar","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, VIMSAR, Burla, Sambalpur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyashree","family":"Padhan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, VIMSAR, Burla, Sambalpur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipsita","family":"Khuntia","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, FM Medical College, Balasore, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumita","family":"Naik","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, VIMSAR, Burla, Sambalpur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswambara","family":"Satpathy","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, VIMSAR, Burla, Sambalpur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"R1-20250225","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: Update on pathophysiology and treatment","volume":"58","author":"Nicholson","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"R2-20250225","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"Zhao","year":"2012","journal-title":"J Clin Invest"},{"key":"R3-20250225","first-page":"1369","article-title":"Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: Case report","volume":"17","author":"Gruszka","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R4-20250225","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","article-title":"Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: A pilot study","volume":"33","author":"Bousquet","year":"2013","journal-title":"Retina"},{"key":"R5-20250225","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0039-6257(02)00338-7","article-title":"Central serous chorioretinopathy and glucocorticoids","volume":"47","author":"Bouzas","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"R6-20250225","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1442-9071.2012.02848.x","article-title":"Central serous chorioretinopathy: A review of epidemiology and pathophysiology","volume":"41","author":"Liew","year":"2013","journal-title":"Clin Exp Ophthalmol"},{"key":"R7-20250225","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"Wang","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R8-20250225","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","article-title":"Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy","volume":"22","author":"Loo","year":"2002","journal-title":"Retina"},{"key":"R9-20250225","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00006982-199616030-00004","article-title":"Indocyanine green videoangiography of older patients with central serous chorioretinopathy","volume":"16","author":"Spaide","year":"1996","journal-title":"Retina"},{"key":"R10-20250225","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/00006982-199911000-00005","article-title":"Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy","volume":"19","author":"Iida","year":"1999","journal-title":"Retina"},{"key":"R11-20250225","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/jovr.jovr_152_17","article-title":"Evaluation of choroidal layer thickness in central serous chorioretinopathy","volume":"14","author":"Hanumunthadu","year":"2019","journal-title":"J Ophthalmic Vis Res"},{"key":"R12-20250225","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/IAE.0b013e31820f4b39","article-title":"Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy","volume":"31","author":"Maruko","year":"2011","journal-title":"Retina"},{"key":"R13-20250225","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"R14-20250225","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/jamaophthalmol.2017.0245","article-title":"Association of a haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy","volume":"135","author":"van Dijk","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R15-20250225","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40123-018-0121-2","article-title":"Eplerenone versus observation in the treatment of acute central serous chorioretinopathy: A retrospective controlled study","volume":"7","author":"Zucchiatti","year":"2018","journal-title":"Ophthalmol Ther"},{"key":"R16-20250225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/08820538.2016.1228418","article-title":"Systemic mineralocorticoid antagonists in the treatment of central serous chorioretinopathy","volume":"32","author":"Yang","year":"2017","journal-title":"Semin Ophthalmol"},{"key":"R17-20250225","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1111\/aos.13491","article-title":"Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study","volume":"95","author":"Schwartz","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"R18-20250225","doi-asserted-by":"crossref","first-page":"e776","DOI":"10.1111\/aos.13665","article-title":"Correlation between morphological characteristics in spectral-domain-optical coherence tomography, different functional tests and a patient's subjective handicap in acute central serous chorioretinopathy","volume":"96","author":"Gerendas","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"R19-20250225","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/IAE.0000000000001649","article-title":"Arandomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior)","volume":"38","author":"Rahimy","year":"2018","journal-title":"Retina"},{"key":"R20-20250225","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","article-title":"Spironolactone for nonresolving central serous chorioretinopathy: A randomized controlled crossover study","volume":"35","author":"Bousquet","year":"2015","journal-title":"Retina"},{"key":"R21-20250225","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/jcm8091271","article-title":"Optical coherence tomography parameters as predictors of treatment response to eplerenone in central serous chorioretinopathy","volume":"8","author":"Borrelli","year":"2019","journal-title":"J Clin Med"},{"key":"R22-20250225","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/jcm8040474","article-title":"Anatomical and functional changes of the retina and the choroid after resolved chronic CSCR","volume":"8","author":"Toto","year":"2019","journal-title":"J Clin Med"},{"key":"R23-20250225","doi-asserted-by":"crossref","first-page":"675295","DOI":"10.3389\/fphar.2021.675295","article-title":"Routine clinical practice treatment outcomes of eplerenone in acute and chronic central serous chorioretinopathy","volume":"12","author":"Fasler","year":"2021","journal-title":"Front Pharmacol"},{"key":"R24-20250225","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","article-title":"Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): A randomised, double-blind, placebo-controlled trial","volume":"395","author":"Lotery","year":"2020","journal-title":"Lancet"},{"key":"R25-20250225","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3928\/23258160-20150422-06","article-title":"Oral eplerenone for treatment of chronic central serous chorioretinopathy: A case series","volume":"46","author":"Salz","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R26-20250225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40942-019-0190-y","article-title":"Short-term eplerenone for treatment of chronic central serous chorioretinopathy;a prospective study","volume":"5","author":"Moein","year":"2019","journal-title":"Int J Retina Vitreous"},{"key":"R27-20250225","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/IAE.0b013e3181be0a83","article-title":"Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy","volume":"29","author":"Imamura","year":"2009","journal-title":"Retina"},{"key":"R28-20250225","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1097\/IAE.0000000000000929","article-title":"Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy","volume":"36","author":"Lee","year":"2016","journal-title":"Retina"},{"key":"R29-20250225","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/eye.2014.219","article-title":"Correlation of subretinal fluid volume with choroidal thickness and macular volume in acute central serous chorioretinopathy","volume":"28","author":"Goktas","year":"2014","journal-title":"Eye (Lond)"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_118_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:24:29Z","timestamp":1787837069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_118_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_118_23","relation":{},"ISSN":["0974-620X","0974-7842"],"issn-type":[{"value":"0974-620X","type":"print"},{"value":"0974-7842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2023-06-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}